Trial of Psilocybin versus Escitalopram for Depression.
Robin L. Carhart-Harris,Bruna Giribaldi,Rosalind Watts,Michelle Baker-Jones,Ashleigh Murphy-Beiner,Roberta Murphy,Jonny Martell,Allan Blemings,David Erritzoe,David J. Nutt +9 more
TLDR
In a phase 2, double-blin... as mentioned in this paper, double-blind comparison between psilocybin and established treatments for depression is conducted using a double-labeling system.Abstract:
Background Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. Methods In a phase 2, double-blin...read more
Citations
More filters
Journal ArticleDOI
Increased global integration in the brain after psilocybin therapy for depression
Richard E. Daws,Christopher Timmermann,Bruna Giribaldi,James D. Sexton,Matthew B. Wall,David Erritzoe,Leor Roseman,David J. Nutt,Robin L. Carhart-Harris +8 more
TL;DR: In this paper , the authors assessed the subacute impact of psilocybin on brain function in two clinical trials of depression using functional magnetic resonance imaging (fMRI) at baseline and 1 d after the 25-mg dose.
Journal ArticleDOI
Increased global integration in the brain after psilocybin therapy for depression
Richard E. Daws,Christopher Timmermann,Bruna Giribaldi,James D. Sexton,Matthew B. Wall,David Erritzoe,Leor Roseman,David Nutt,Robin L. Carhart-Harris +8 more
TL;DR: In this paper , the authors assessed the subacute impact of psilocybin on brain function in two clinical trials of depression using functional magnetic resonance imaging (fMRI) at baseline and 1 d after the 25-mg dose.
Journal ArticleDOI
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
TL;DR: Psilocybin is being studied for use in treatment-resistant depression in a phase 2 double-blind trial, where participants were randomly assigned to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support as mentioned in this paper .
Journal ArticleDOI
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder
Michael P. Bogenschutz,Stephen E. Ross,Snehal Bhatt,Tara Baron,Alyssa A. Forcehimes,Eugene M. Laska,Sarah E. Mennenga,Kelley C O’Donnell,Lindsey T. Owens,Samantha K. Podrebarac,John Rotrosen,J. Scott Tonigan,Lindsay M Worth +12 more
TL;DR: The results in this trial showed that psilocybin administered in combination with psychotherapy produced robust decreases in the percentage of heavy drinking days compared with those produced by active placebo and psychotherapy.
Journal ArticleDOI
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up
Natalie Gukasyan,Alan K. Davis,Frederick S. Barrett,Mary P Cosimano,Nathan D. Sepeda,Matthew W. Johnson,Roland R. Griffiths +6 more
TL;DR: In this article , the authors examined the efficacy and safety of psilocybin-assisted treatment through 12 months in participants with moderate to severe depression who received two doses with supportive psychotherapy.
References
More filters
Journal ArticleDOI
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis
Andrea Cipriani,Andrea Cipriani,Toshi A. Furukawa,Georgia Salanti,Anna Chaimani,Anna Chaimani,Anna Chaimani,Lauren Z Atkinson,Lauren Z Atkinson,Yusuke Ogawa,Stefan Leucht,Henricus G. Ruhé,Henricus G. Ruhé,Erick H. Turner,Julian P T Higgins,Matthias Egger,Nozomi Takeshima,Yu Hayasaka,Hissei Imai,Kiyomi Shinohara,Aran Tajika,John P. A. Ioannidis,John R. Geddes,John R. Geddes +23 more
TL;DR: This work aimed to update and expand previous work to compare and rank antidepressants for the acute treatment of adults with unipolar major depressive disorder, and found that all antidepressants were more effective than placebo.
Journal ArticleDOI
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Charles S. Grob,Alicia L. Danforth,Gurpreet S. Chopra,Marycie Hagerty,Charles R. McKay,Adam L. Halberstadt,George R. Greer +6 more
TL;DR: This study established the feasibility and safety of administering moderate doses of psilocybin to patients with advanced-stage cancer and anxiety and revealed a positive trend toward improved mood and anxiety.
Journal ArticleDOI
Human hallucinogen research: guidelines for safety.
TL;DR: The unique history of human hallucinogens research is discussed, the risks of hallucinogen administration and safeguards for minimizing these risks are reviewed, and carefully conducted research may inform the treatment of psychiatric disorders, and may lead to advances in basic science.
Journal ArticleDOI
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Alan K. Davis,Alan K. Davis,Frederick S. Barrett,Darrick G. May,Mary P Cosimano,Nathan D. Sepeda,Matthew W. Johnson,Patrick H. Finan,Roland R. Griffiths +8 more
TL;DR: This randomized clinical trial examines the efficacy of psilocybin as an adjunct to psychotherapy and other treatments for major depressive disorder.
Journal ArticleDOI
The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future
TL;DR: In this circumspective piece, RLC-H and GMG share their opinions on the promises and pitfalls of renewed psychedelic research, with a focus on the development of psilocybin as a treatment for depression.